Durata Therapeutics Email Format

Pharmaceutical ManufacturingIllinois, United States11-50 Employees

Durata Therapeutics is a Chicago, Illinois-based biopharmaceutical company founded in 2009 that operates in the pharmaceutical manufacturing sector with a focus on infectious diseases and acute illnesses. The company aims to become an integrated biopharmaceutical enterprise, pursuing development and targeted acquisitions of therapeutics for hospital and acute-care settings. Its lead product candidate, dalbavancin, is in late-stage clinical development for acute bacterial skin and skin structure infections caused by Gram-positive bacteria, including MRSA and certain Streptococcal species.

Dalbavancin is described as a second-generation, semi-synthetic lipoglycopeptide designed for once-weekly intravenous dosing to support treatment in both inpatient and outpatient settings, with the goal of reducing hospital stays and overall cost of care. The organization operates as a relatively small operation, with a modest workforce focused on advancing its clinical program and strategic objectives. In 2017, Durata Therapeutics was acquired by Actavis (now Allergan), integrating its portfolio into a larger pharmaceutical enterprise.

Sign up for free to view info

Company overview Employee directory